Company developing stem cell-based diabetes device gains $10.6M

07/12/2013 | San Diego Union-Tribune

ViaCyte has obtained $10.6 million in financing that the company says would go toward its VC-01 device, which uses cells derived from human embryonic stem cells to treat patients with type 1 diabetes. The company already has tested the device in animals and hopes to launch human clinical studies next year, CEO Paul Laikind said.

View Full Article in:

San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN